Ad
related to: how to treat sjogren's naturally treatment plan template
Search results
Results from the WOW.Com Content Network
Sjögren's disease (SjD) [8] [9] (previously known as Sjögren syndrome or Sjögren's syndrome (SjS, SS)) is a long-term autoimmune disease that primarily affects the body's exocrine glands, particularly the lacrimal and salivary glands.
Etanercept mimics the inhibitory effects of naturally occurring soluble TNF receptors, the difference being that etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly extended half-life in the bloodstream, and therefore a more profound and long-lasting biologic effect than a naturally occurring soluble TNF ...
Sjögren–Larsson syndrome is a rare autosomal recessive form of ichthyosis with neurological symptoms. [1]: 485 [2]: 564 [3] It can be identified by a triad of medical disorders.
A nurse tends to an infusion gene therapy treatment for Kendric Cromer, 12, at Children's National Hospital in Washington, Sept. 11, 2024. Cromer is one of the first children ever to be treated ...
Eating You Alive is a 2018 health documentary film about why Americans are suffering from chronic diseases such as cardiovascular disease, diabetes, obesity, autoimmune disease, among other diseases, and whether the outcome can be changed. [1]
Norepinephrine reuptake inhibitors (NRIs) such as reboxetine prevent the reuptake of norepinephrine, providing a different mechanism of action to treat depression. However reboxetine is no more effective than the SSRIs in treating depression. In addition, atomoxetine has found use in the treatment of ADHD as a non-addictive alternative to Ritalin.
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Ad
related to: how to treat sjogren's naturally treatment plan template